Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 3, 2002, Pages 399-406

  Sands, B E ^a   Winston, B D ^b   Salzberg, B ^c   Safdi, M ^e   Barish, C ^d   Wruble, L ^f   Wilkins, R ^g   Shapiro, M ^g   Schwertschlag, U S ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b West Houston Medical Center   (United States)

^c Atlanta Gastroenterology Associates   (United States)

^d WAKE RESEARCH ASSOCIATES   (United States)

^e Consultants for Clinical Research ^*  (United States)

^f Mid South Clinical Research Institute   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; PLACEBO; RECOMBINANT INTERLEUKIN 11;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HEADACHE; HUMAN; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; CROHN DISEASE; EDEMA; FEMALE; HEADACHE; HUMANS; INTERLEUKIN-11; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0036186051     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01179.x     Document Type: Article

References (27)

1. Inflammatory bowel disease: Etiology and pathogenesis
2. Treatment of inflammatory bowel disease from now to the millennium
3. Intestinal epithelial hyperpermeability. Mechanisms and relevance to disease
4. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease
5. Review article: Chemokine production by intestinal epithelial cells: A therapeutic target in inflammatory bowel disease?
6. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease
7. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells
8. Biologic therapy for inflammatory bowel disease
9. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
10. Safety tolerance pharmacokinetics and pharmacodynamics of recombinant interleukin-10 (SCH 52000) in patients with steroid refractory Crohn's disease
11. Preliminary evaluation of safety and activity of recombinant human interleukin-11 in patients with active Crohn's disease
12. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study
13. A new measure of health status for clinical trials in inflammatory bowel disease
14. Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1
15. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein
16. Interleukin-11: Review of molecular, cell biology, and clinical use
17. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats
18. Dose response and schedule studies of recombinant human interleukin-11 in acetic acid-induced colonic injury in rats
19. Recombinant human interleukin-11 (rhIL-11) decreases inflammatory bowel disease in HLA-B27 transgenic rats
20. rhIL-11 decreases the severity of acetic acid-induced colonic injury in rats
21. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis
22. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production
23. Predominant role of NF-kappa B p65 in the pathogenesis of chronic intestinal inflammation
24. IL-11 a pleiotropic cytokine: Exciting new effects of IL-11 on gastrointestinal mucosal biology
25. Intestinal permeability of 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives
26. Importance of intestinal mucosal immunity and luminal bacterial cell wall polymers in the aetiology of inflammatory joint diseases
27. Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects